Modern Meadow
Develops biofabricated leather alternatives using synthetic biology and bio-design technologies, with applications in fashion, automotive, and accessories.
- CEO / Founder
- David Williamson
- Team Size
- 51-200
- Stage
- Active
- Total Funding
- $196M
- Latest Round
- Series C
- Key Investors
- Key Partners Capital; Horizons Ventures; Iconiq Capital; Evonik Venture Capital; ARTIS Ventures; Temasek; Breakout Ventures; Red Swan Ventures; Collaborative Fund
Technology & Products
Key Products
INNOVERA (formerly BIO-VERA); Bio-Tex; Bio-Alloy platform; Bio-F@RM technology
Technological Advantage
Biofabrication process enables production of leather-like materials with high sustainability (e.g., 90%+ renewable carbon), protected by proprietary technologies and partnerships.
Differentiation
Value Proposition
Provides high-performance, sustainable leather alternatives with over 90% renewable carbon content, reducing environmental impact and enabling scalable adoption without animal inputs.
How They Differentiate
Focus on biofabricated leather alternatives using synthetic biology, with commercial-scale production (500,000+ sq m/year) and partnerships with major brands like Mercedes-Benz.
Market & Competition
Target Customers
Brands and manufacturers in fashion, automotive, footwear, and accessories seeking sustainable, animal-free materials.
Industry Verticals
Fashion; Automotive; Footwear; Accessories; Outdoor gear
Competitors
Ohoskin; Ecovative; MycoWorks
Growth & Milestones
Growth Metrics
Annual revenue reported as $32M with 165 employees; production capacity of over 500,000 square meters per year for BIO-VERA.
Major Milestones
Founded in 2011; Launched ZOA prototype in 2017; Secured $130M Series C in 2021; Appointed David Williamson as CEO in 2024; Announced commercial-scale production in 2024
Notable Customers
Mercedes-Benz; MAES Paris; Bellroy